Table 3. Oncogenes and Its Potential Therapeutic Targets in Treating Mucoepidermoid Carcinoma.

Targeted agent	Oncogenes involved in MEC
Sorafenib	VEGF and ANG2
Nintedanib	VEGFR, FGFR, and PDGFR
Trastuzumab	HER2/neu
Lapatinib	EGFR and erbB2
ANA-12	TrkB and BDNF

MEC: mucoepidermoid carcinoma; VEGF: vascular endothelial growth factor; VEGFR: VEGF receptor; FGFR: fibroblast growth factor receptor; PDGFR: platelet-derived growth factor receptor; HER2/neu: human epidermal growth factor receptor 2; EGFR: epidermal growth factor receptor; erbB-2: receptor tyrosine-protein kinase; TrkB: tropomyosin receptor kinase B; BDNF: brain-derived neurotrophic factor.